Leveraging Cells to Treat Disease
Through our technologies we leverage the potential of our cells by enabling the body to rebalance irregularities (T Regulatory Technology), and increase blood flow (CD34+ Cell Technology).
CD34+ Cell Technology
Heart attack, chronic heart failure, critical limb ischemia, and stroke are all caused by an acute or chronic deficit in the supply of oxygenated blood. One of the body’s natural responses to areas with low levels of oxygenated blood is the recruitment of CD34+ cells to those tissues. Caladrius’s CD34 technology leverages the body’s natural repair mechanism to induce the development of new blood vessels, preventing tissue death by improving blood flow. Read more.